Novartis to Highlight Updated Data from the P-III (NATALEE) Study of Kisqali (Ribociclib) for Treating Early Breast Cancer (EBC) at ESMO 2024
Shots:
- Novartis will highlight 4yrs. post-hoc analysis from P-III (NATALEE) study (conducted in partnership with TRIO) assessing the safety & efficacy of Kisqali + endocrine therapy (ET) as an adj. treatment vs ET alone for stage II & III HR+/HER2- EBC at ESMO 2024
- Updated analysis showed reduced risk of recurrence by 28.5%, iDFS rates were 88.5% vs 83.6% in ITT population, 93.9% vs 89.6% in AJCC tumor stage II group, 84.3% vs 78.4% in AJCC tumor stage III group and 92.1% vs 87% in node -ve disease group. Results were similar in the 2EPs with a trend favoring improved OS (additional OS follow-up is underway)
- The data has been submitted to the US FDA & EMA, with the FDA’s decision anticipated in Q3’24
Ref: Novartis | Image: Novartis
Related News:- Novartis Presents P-III Trial (NATALEE) Results of Kisqali (ribociclib) for Early Breast Cancer at ESMO Virtual Plenary
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
